Breast Cancer

An emerging focus is aligning targeted, safe, and effective therapies with patient goals.

New study results show that the drugs, which block estrogen production, are more effective for premenopausal and postmenopausal women.

Christopher Mast, MD, vice president of clinical informatics at Epic, explains his outlook for the future in the field of oncology in light of the ongoing delays in cancer screenings rates.

Christopher Mast, MD, vice president of clinical informatics at Epic, explains the level to which cancer screening rates would need to rise to meet pre-pandemic rates.

Results from a clinical trial led by investigators at the National Cancer Institute show that 28 of 42 women with tumors generated a reaction.

Christopher Mast, MD, vice president of clinical informatics at Epic, discusses research that showed that cancer screening rates in 2021 rebounded from the low rates at the start of the pandemic, but not significantly.

Abemaciclib (Verzenio) was recently approved in combination with endocrine therapy for the adjuvant treatment of adult patients with HR–positive, HER2-negative, node-positive, early breast cancer at high risk of recurrence.

Trastuzumab deruxtecan is a HER2-directed antibody drug conjugate being developed by both AstraZeneca and Daiichi Sankyo.

Knocking down MAPK4 resulted in the cells’ increased sensitivity to PI3K inhibitors and reduced breast cancer growth.

Incorporating mental distress screenings during cancer care have been historically difficult, despite the fact that these patients tend to be vulnerable to mental health challenges.

Anxiety disorders and depression were cited by more than 80% of oncologists as the types of mental health distress seen most often for patients.

Commonly used medications may influence responses to checkpoint inhibitors among patients with cancer.

Patients with hormone receptor-positive breast cancer doubled their median progression-free survival following a switch to fulvestrant plus palbociclib.

Patients with breast cancer treated with pyrotinib plus capecitabine had a 31% lower risk of death than those treated with lapatinib and capecitabine

New technology provides information on the benefit of adding atezolizumab to chemotherapy as a neoadjuvant treatment for patients with early high-risk and locally advanced triple-negative breast cancer.

Uterine cancers that developed in patients with breast cancer treated with tamoxifen had fewer phosphoinositol-3-kinase (PI3K) pathway mutations and may have been driven by tamoxifen-induced PI3K pathway activation.

Since its initial approval in 2016 for urothelial carcinoma, atezolizumab has received FDA approval for an additional 5 types of carcinomas.

Fulvestrant is also the only SERD approved for patients with breast cancer, according to the researchers.

Olaparib is a first-in-class PARP inhibitor and is the first targeted treatment to block DNA damage response in cells or tumors with a deficiency in homologous recombination repair.

Genomic analyses show promise for patients with metastatic breast cancer, reinforcing genomics as a part of the pathway of care.

Tamoxifen is given to many patients—specifically premenopausal patients—with breast cancers that express the estrogen receptor, which drives breast tumor growth.

Certain patients with breast cancer treated with an aromatase inhibitor plus palbociclib (Ibrance) could benefit from an early switch to fulvestrant (Faslodex) plus palbociclib, study finds.

Pyrotinib combined with capecitabine found to improve overall survival in patients with previously treated HER2-positive metastatic breast cancer.

Further, among premenopausal women, those who received chemotherapy had a 40% relative improvement in IDFS compared to those administered endocrine therapy alone.

The diagnostic tool widens the age group of individuals who can get tested and can be used in conjunction with a mammogram.

Olaparib was the first PARP inhibitor to be developed and has been the most studied.

Breast cancer found to be the most expensive type of the disease, costing approximately $3.4 billion in the United States.

Pertuzumab is indicated for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

Atrial fibrillation was more common in those not treated with radiation (66.5%) or surgery (23.5%) as first-line treatment compared with 52.3% and 10.4%, respectively.

Sacituzumab govitecan-hziy is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received 2 or more prior systemic therapies, at least 1 of which for metastatic disease.